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Background: Case management is a client-centered approach to improve the
coordination and continuity of service delivery, especially for persons with substance use
disorders (SUD) and multiple and complex support needs. This intervention supports
individuals by helping them identify needed services, facilitate linkage with services, and
promote participation and retention in services. However, it is questionable whether
case management is equally effective in promoting recovery and aspects of personal
functioning. The objective was to conduct an updated meta-analysis and to assess
whether case management was more effective than treatment as usual (TAU) among
persons with SUD for improving treatment-related (e.g., successful linkage with and
retention in treatment) as well as personal functioning outcomes (e.g., substance use).
Methods: This meta-analysis focuses on randomized controlled trials (RCTs) that
included persons with alcohol or drug use disorders and compared case management
with TAU. To be eligible, interventions had to meet core case management functions as
defined in the literature. We conducted searches of the following databases to May 2017:
the Cochrane Drugs and Alcohol Specialized Register, CENTRAL, PubMed, Embase,
CINAHL, andWeb of Science. Also, reference lists of retrieved publications were scanned
for relevant (un)published studies.
Results: The overall effect size for case management compared to TAU across all
outcome categories and moments was small and positive (SMD = 0.18, 95% CI
0.07–0.28), but statistically significant. Effects were considerably larger for treatment
tasks (SMD = 0.33, 95% CI 0.18–0.48) than for personal functioning outcomes (SMD
= 0.06, 95% CI −0.02 to 0.15). The largest effect sizes were found for retention in
substance abuse treatment and linkage with substance abuse services. Moderator
effects of case management models and conditions were assessed, but no significant
differences were observed.
Conclusions: The primary results from earlier meta-analyses were supported: case
management is more effective than TAU conditions for improving outcomes, but this
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effect is significantly larger for treatment-related tasks than for personal functioning
outcomes. Case management can be an important supplement to available services
for improving linkage and retention, although further research is needed to assess its
potential for supporting recovery from a longitudinal perspective.
Keywords: case management, addiction, systematic review, effectiveness, treatment
INTRODUCTION
Rationale
Substance use disorders (SUD) are associated with a wide range
of consequences, including adverse health, social and economic
outcomes (1–4). The health status of persons with alcohol and
drug problems is often negatively affected by their substance
abuse and SUDs contribute significantly to the global burden
of disease (4, 5). Consequently, life expectancy and disability
adjusted life years are often much lower among this population
(6, 7). The co-existence of SUDs and other psychiatric disorders
is widely documented and poses specific treatment challenges
(8). Moreover, people with alcohol or drug use problems
are more likely to be negatively affected on key employment
measures such as being employed (9), maintaining productivity,
and remaining in the workforce (10). Housing, judicial and
relational problems are also pervasive among persons with
SUDs, including a negative impact on partners, parents and
children (11).
Persons with SUDs frequently have significant problems
functioning in multiple areas of their lives, which seriously
affects their social reintegration and recovery process (12). Some
of these problems may have preceded substance abuse, or are
direct results of it. In either instance, few treatment programs
are equipped to provide the broad range of services necessary
to meet the diverse support needs of this population (2, 13–
15). SUDs are commonly recognized as chronic and relapsing
disorders, requiring continuous support to promote recovery
(2, 16, 17). The observation that many persons with SUDs
have other lasting problems in addition to using substances
was the main impetus for implementing case management as
an addition to traditional treatment services from the 1980’s
onwards (18).
Following deinstitutionalization and the emerging recovery
movement, case management was successfully adapted to the
treatment and community-based support of various mental
health populations in the United States, Canada, Australia
and Europe (19–23). Its potential effectiveness for persons
with SUDs was suggested in various narrative reviews (14,
18). Multiple randomized clinical trials of substance abuse
case management have examined the intervention’s impact on
varied substance abusing populations: dually diagnosed persons,
HIV infected drug users, opiate dependent individuals, female
substance abusers, crack cocaine users, and homeless persons.
Substance abuse casemanagement has been adapted to work with
persons in and out of treatment and in settings as diverse as
treatment programs, emergency wards, welfare offices, correction
and probation facilities, homeless shelters, and centralized
intake units.
Case management is an intervention designed to enhance
coordination and continuity of care and support, especially
for persons with multiple, and complex needs (2). One of the
first definitions described case management as “that part of
substance abuse treatment that provides ongoing supportive
care to clients and facilitates linking with appropriate helping
resources in the community” [(24), p. 182]. Case management
is an intervention that supports individuals by helping them
“identify needed services, select the most appropriate services
available, facilitate linkage with services and promote continued
retention in services by monitoring participation, coordinating
activities of multiple services when present and when necessary,
and advocating for continued participation” [(25), p. 615].
In clinical trials, case management has been associated with
over 450 different types of outcomes, which were clustered
around 10 broad outcome categories in a meta-analysis focusing
on studies published until 2011 (25). The association of case
management with so many different outcomes suggests very
unfocused expectations about where casemanagement’s value lies
along the treatment continuum.
As in mental health care, several models of case management
are identified, including brokerage, generalist, intensive,
strengths-based, and clinical case management, as well as
assertive community treatment (18). These different models
facilitate the above-mentioned goals somewhat differently.
Brokerage case management is intended to address some of these
functions in a very minimalist manner in one or two contacts.
Assessment, planning, linking, monitoring, and advocacy are
core case management functions and central to generalist or
standard case management. Intensive case management involves
intensive contacts between case manager and client, although
the extent of such involvement is not always specified. Assertive
community treatment includes the provision of services by a
multidisciplinary team, as well as referral to outside services and
resources. Strengths-based case management focuses on utilizing
individuals’ strengths and assets and the use of informal rather
than formal supportive networks. Finally, the clinical model
of case management combines case management with clinical
activities, for example psychotherapy and counseling (2).
Objectives and Research Questions
Case management is likely to support the recovery process,
but few studies have looked beyond substance use outcomes
or included substantial follow-up periods. Also, findings from
available systematic reviews are limited to narrative and
global appreciations of study findings, repeatedly stressing its
importance for improving individuals’ overall functioning and—
to a certain extent—substance use outcomes, and for enhancing
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linkage and retention (14, 18, 26–29). Meta-analyses offer
additional opportunities to statistically synthesize data from
various studies and to calculate effect sizes per study and outcome
category, controlling for sample size, and various follow-up
moments (30). Available meta-analyses of substance abuse case
management are outdated (2) and/or focused on a variety of
outcomes rather than effects of single studies (25).
This updated review will provide evidence either supporting
or refuting the earlier findings, which will be discussed from
a recovery perspective. The additional studies available for
this review can also provide more details about moderators
that might affect case management’s efficacy. The objectives
of this meta-analysis are threefold: (1) to assess the efficacy
of case management for linking persons with SUDs with
services they need and promoting treatment retention compared
with ‘treatment as usual’ (TAU); (2) to evaluate whether case
management positively impacts substance use and other life
domains to a larger extent than standard treatment; (3) to
study the role of potential moderating variables (e.g., type
of population served, setting, model of case management,
implementation fidelity affect case management outcomes). This
review will address the critical questions of: (1) Is substance
abuse case management efficacious compared with TAU; (2) Is
case management equally effective in improving treatment task
and personal functioning outcomes; (3) Is the effect of substance
abuse case management the same across all outcome categories
and models?
METHODS
Study Design
This study is a meta-analysis of randomized controlled trials
(RCTs) that have evaluated the efficacy of case management,
reporting at least one follow-up measurement and one or
multiple outcome indicators. Only RCTs that compared (a
specific model of) case management with TAU were included.
Studies were excluded if the randomization procedure was
stopped or violated at some point, resulting in non-equivalent
groups. In case the experimental and control condition received
different pharmacological interventions, studies were excluded
[see also (2, 29)].
Participants, Intervention,
and Comparators
The study sample consisted of persons with a SUD (abuse or
dependence of any legal or illegal substance), not necessarily
confirmed by a DSM diagnosis. Studies including subjects with
other physical or mental health problems were eligible, if the
entire sample had a SUD.
If manuscript authors called an intervention “case
management,” the intervention was assessed based on the case
management criteria developed by the US National Association
of Social Workers (31). The proposed case management
intervention had to meet at least four of the five functions of case
management recognized by the NASW (assessment, planning,
advocacy, linking, monitoring/evaluation) (25). In those
instances where the intervention did not meet these criteria, it
was excluded from the review. Interventions not labeled “case
management” by manuscript authors could fit≥4 NASW criteria
and be included in the meta-analysis. Since case management
has been applied for more than 30 years in the US (24), some
trials have used it as part of a more comprehensive intervention
for persons with SUDs (e.g., coordinated/integrated treatment)
or combined with another intervention (e.g., motivational
interviewing, vouchers or money to purchase treatment).
Studies were excluded if it was impossible to disentangle case
management effects from these of other interventions.
Only studies that compared casemanagement with “treatment
as usual” (TAU), as defined by the study authors, were selected.
TAU may include various interventions called “standard of care,”
“usual care,” or “standard treatment,” but generally refers to
treatment as it is commonly provided. Case management has also
been applied as a control condition in some studies, assuming
its outcomes to be inferior than these of the experimental
condition. Although inclusion of such studies could counter
potential publication bias (32), these were excluded given the
wide variation in type and intensity of case management as
control condition and the loose description of these practices.
Also, studies in which one case management model was
compared with another were not included, since this was
regarded a comparison of different modalities/intensities of
the same intervention. In the absence of a non-case managed
control condition, it was unclear which case management
model should be regarded as control condition. Finally, studies
that compared case management with clearly defined active
(therapeutic, behavioral, or motivational) interventions [e.g.,
contingency management, motivational interviewing (25)] were
beyond the scope of this review.
Systematic Review Protocol
As case management is implemented among various populations
with diverse objectives (2), it has been associated with hundreds
of different outcomes. According to a review by Rapp and
colleagues (25), case management’s effectiveness has been
evaluated across at least ten outcome categories, including
over 450 different outcome measures. For the purpose of this
review, the same 10 categories will be assessed, including diverse
measures of each outcome. The first five categories relate to
personal functioning outcomes and refer to changes in the
behavior of persons with SUDs that are often reported in the
recovery literature: reductions in substance use, risk behavior and
legal involvement; improved health status and social functioning.
The second group of treatment-related outcomes reflects the
processes of treatment that can conceivably be affected by case
management: linkage and retention in both substance abuse
treatment itself and in referral to supportive, ancillary services.
(1) Substance use (e.g., self-reported alcohol and drug use,
biological markers, problem severity as measured by a
standardized instrument).
(2) Physical and mental health status (e.g., number of days
in a hospital for physical/psychological problems, problem
severity, quality of life).
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(3) Legal status (e.g., number of days incarcerated,
problem severity).
(4) Social inclusion, covering employment functioning, social
and family relationships, and living situation (e.g., income
from work, homelessness, problem severity, extent of the
social network).
(5) Risk behavior, including drug and sexual risk behavior.
(6) Linkage (self-reported or administratively verified) with
substance abuse services, including detox, outpatient, or
residential treatment or aftercare).
(7) Linkage with ancillary services that are supportive of other
needs of persons with SUDs, such as housing, employment,
mental health, and medical services.
(8) Retention (self-reported or administratively verified)
in substance abuse services (e.g., number of days
of contact/treatment).
(9) Retention in ancillary services (e.g., number of days
of contact).
(10) Satisfaction with treatment [e.g., individuals’ satisfaction,
acceptance or attitude about the treatment experience (in
substance abuse and ancillary services)].
In case several outcome measures were reported in a given
category, a single effect size was computed for each area per study,
by averaging the effect sizes for each category (25). The outcome
categories were assessed at all available follow-up moments and
an averaged effect size per study across all follow-up moments
was calculated.
Search Strategy
Both electronic and manual searches were undertaken to identify
papers, journal articles, research reports and book chapters for
this review. We built on the search strategy of a previously
published (withdrawn) Cochrane review (2) and updated this
search by identifying relevant studies that met the predefined
inclusion criteria in following electronic databases (search period
January 2006 to May 2017): Web of Science (Thomson Reuters),
EMBASE (Ovid), MEDLINE (PubMed), the Cochrane Drugs
and Alcohol Group Specialized register and the Cochrane
Central Register of Controlled Trials. We combined search
terms that could identify the intervention (“case management”;
“casemanagement”; “case managed”), population (“substance use
disorders,” “addiction,” “substance abuse” or “dependence”), type
of study (“randomized controlled trial”) and its focus (“efficacy,”
“effectiveness,” “outcomes,” “evaluation”). Databases of ongoing
clinical trials were also searched (www.isrctn.com and www.
clinicaltrials.gov). We scanned the reference lists of retrieved
reviews, journal articles, conference abstracts, and gray literature
for other relevant (un)published studies (2). There were no
language or publication year restrictions.
Data Sources, Studies Sections,
and Data-Extraction
Two authors (RCR, WVDP) independently screened the
abstracts of all publications that were obtained through the search
strategy. In case of disagreement, the study was assessed by a
third author (JDM) and discussed between the three assessors.
Two authors (RCR, WVDP) independently assessed the full
texts of potentially relevant studies for inclusion. Again, any
disagreement was resolved by involving a third author (JDM) and
discussing eligibility between all three authors [see also (2)].
Two authors (RCR, WVDP) extracted data from the
selected studies. WVDN checked all data extraction files.
Any inconsistencies or obscurities were resolved by discussion
between all three authors. Following information was extracted:
number and characteristics of study participants, authors’ names
and country of origin, types of outcomes and potential conflicts of
interest. Additional variables (seeTable 1) were extracted that are
particularly relevant for case management: model and location
of case management, type of substance abusers, treatment
status of participants upon study entry, presence/absence of a
manual/protocol, or supervision, fidelity assessment (2). Also,
the length of the follow-up period from which outcomes were
presented was recorded.
As this is an update of a previously published review [(2), p. 5],
we used the same protocol for data-extraction and extracted any
relevant data for each of the outcome categories described above.
For example, concerning drug use, if a study reported the ASI
drugs severity and the number of abstinent days for each subject,
we registered all data that allowed us to compute (averaged) effect
sizes for each indicator. Data had to include either means or
standard deviations for both the control and experimental group,
a proportion for both the control and experimental group or
statistics that allowed us to calculate an effect size, such as a
univariate F-statistic, t-statistic, or a χ²-statistic with one degree
of freedom. For each outcome measure, we recorded data on
the degree of change in the experimental and comparison group,
when available (2).
Risk of Bias Assessment
Three authors (WVDP, RCR, WVDN) independently assessed
the risk of bias in included studies. To make these judgements,
the criteria indicated by the Cochrane Handbook for Systematic
Reviews of Interventions were used (32). The domains of
sequence generation and allocation concealment (avoidance
of selection bias) were assessed by a single entry for each
study. Blinding of participants, personnel, and outcome assessor
(avoidance of performance bias and detection bias) was
considered separately for objective (e.g., drop-out, substance
use measured by urine analysis) and subjective outcomes
(e.g., severity of withdrawal symptoms, self-reported use of
substances). We included incomplete outcome data (avoidance
of attrition bias) for all outcomes, except for drop-out from
treatment, which is very often the primary outcome measure in
substance abuse trials.
When several indicators reflecting the same construct are
measured but only statistically significant effects are reported,
publication bias may arise (2), leading to inflated overall effect
estimates in a meta-analysis. The effect of publication bias (and
therefore the inflation of the overall effect size) is likely to be
larger for small studies: whereas for large studies even small
observed effect sizes will be statistically significant, for small
studies only the largest observed effect sizes will be statistically
significant. We used visual inspection of funnel plots (plots of
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the effect estimate from each study against the sample size or
effect standard error) to explore whether there is evidence for a
negative association between the observed effect size and sample
size. We want to note however that such a negative association
is to be considered merely as an indication for publication or
reporting bias, because it may be induced by other factors,
such as an association between the study size and characteristics
of the population or the intervention, or merely the role of
chance. We inspected funnel plot symmetry when there were
at least 10 studies included in the meta-analysis for a specific
outcome measure.
Data-Analysis
For each clinical trial, we calculated effect sizes separately for
each outcome measure, as in the original meta-analysis [(2),
p.5]. In case multiple indicators were reported that were relevant
for a single outcome measure (e.g., number of drinks/day,
days abstinent), we computed an effect size for each indicator
separately, before averaging effect sizes per outcome. We
also calculated all effect sizes separately for various follow-up
moments. If feasible, measures with unknown or unsatisfactory
psychometric properties were dropped from these analyses.
Exceptions were: data from registers (e.g., treatment records,
prison records) and objective data related to persons’ living
situation (e.g., employment status, receiving welfare benefits).
Also, we used data from urine tests and other biological tests for
analyses, even if no specific data on the validity of these tests were
provided (2).
There was much variation in the way the results were reported
in the primary studies. For continuous data, we used Hedges’ g
and corresponding standard errors, corrected for small-sample
bias. If this information was not available from the primary
studies, we made use of summary statistics (like means, standard
deviations and group sizes) to calculate Hedges’ g and standard
error, or converted reported effect sizes (e.g., Pearson’s r) or
test statistics (e.g., t-statistics) to Hedge’s g. For dichotomous
outcomes, we used the log odds ratio (LOR) and standard
error. If these were not reported, we calculated the LOR and
standard error using information on odds ratios, cell frequencies,
proportions and/or test statistics. Afterwards, these LORs were
converted to Hedges’ g. All calculations and conversions were
done in Comprehensive Meta-Analysis (CMA) (33).
For the majority of the included trials, we had multiple
observed effect sizes. One of the reasons is that for some clinical
trials, we found effect sizes in multiple publications. This induced
dependencies: effect sizes from the same study are likely to be
related. We dealt with these dependencies by calculating the
mean effect size for each study, before combining these averages
in a traditional meta-analysis.
Heterogeneity was assessed by performing Q-tests for
homogeneity. The between-study variance, tau², was estimated
as well. Moderator analyses were conducted to explore reasons
for heterogeneity: when sufficient effect sizes were available (i.e.,
at least two per category), effect sizes were divided in categories
and the effect of these categorical moderators was evaluated
using the Q-test. By doings so, the effect of following categorical
moderators was studied: case management model, treatment
status (in/out of treatment), recruitment setting (community,
welfare service, substance abuse treatment, criminal justice
setting), drug use preference, and implementation quality (use of
a manual/protocol and/or supervision).
Because the individual trials differ from each other in many
aspects that may have an influence on the size of the effects,
it is unlikely that the population effect sizes are exactly the
same in all studies, not even after correcting for the influence of
the moderator variables that were coded in our meta-analyses.
Therefore, we made use of random effects models that take
into account a possible (residual) heterogeneity in population
effect sizes. To account for the risk of bias, we explored the
moderating effects of allocation concealment (selection bias),
blinding of outcome assessor (detection bias) and attrition bias.
We performed sensitivity analyses by excluding trials with high
risk of bias from the analyses. No differences were found for the
primary outcomes between trials with a different level of risk of
bias; when we excluded trials at high risk of bias for the three
domains, it did not change conclusions.
RESULTS
Study Selection and Characteristics
Based on the search strategy outlined above, 2,515 unique
documents were identified (see Figure 1). One hundred and fifty-
seven (157) studies received in-depth screening, which led to the
elimination of 139 studies for a variety of reasons. Reasons for
exclusion were the following: the study was not a randomized
clinical trial or not truly randomized (n = 40); not all of the
study participants were persons with SUDs or at least some
of the participants were children/adolescents (n = 32); case
management was combined with another intervention and the
effects of case management could not be separated out (n =
25), or the intervention did not meet the requirements for case
management established in the protocol (n = 11). In other
studies, two models of case management were compared (n = 9)
or case management was compared with an active intervention
rather than TAU (n = 14). In a few studies, reported outcomes
did not conform to the study protocol (n = 5) and three studies
that were otherwise eligible were excluded, because findings were
not presented in a form that allowed calculation of an effect size.
The 18 eligible studies were combined with 13 studies from
a previously published Cochrane review, resulting in 31 studies
available for this meta-analysis. Two studies from the Cochrane
review (n = 15) were removed as one appeared not randomized
(34), while the other didn’t compare case management to TAU
(35). The 31 included studies were conducted as part of 21
different RCTs; some clinical trials generated more than one
distinct published study.
Core characteristics of included trials and studies are outlined
in Table 1 and are briefly described below. Sixteen of the 21
clinical trials resulted in one study/publication, four trials were
published as two publications (40, 41, 51, 56–59, 65) and (55,
56) and one trial was reported in six studies/publications (42–
47). Case management was most frequently compared with
existing referral procedures (11 trials). Other trials compared case
management with existing treatment (4 trials), parole supervision
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FIGURE 1 | PRISMA study flow diagram.
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(n= 2), standard probation (n= 2), routine outreach (n= 1), or
passive referral (n= 1).
A total of 7,431 unduplicated participants were randomized
in the 21 clinical trials. The mean size of the trials was 354
subjects, ranging from a small study with 41 subjects (38) to
a large trial including 1,369 subjects (7). Two typologies of
substance use problems could be discerned: heroin or cocaine
users involved in injectable drug use (IDU) (6 trials) and
polysubstance abusers, that is, a mixed group of substance
abusers where no one type of drug predominated (10 trials).
Two trials contained a relatively homogenous substance abusing
population consisting of individuals who were alcohol dependent
(39, 64). Typically, study authors reported findings on specific
subpopulations, including individuals who were homeless, dually
diagnosed, HIV positive or female only (with children). Some
of the study populations consisted of substance abusers involved
in the criminal justice system: individuals on probation (7, 60)
or persons on parole (36, 61). The Morgenstern trials (12, 55)
involved substance users in public welfare settings, while two
trials recruited individuals in central intake units (48, 57). At the
time they entered the study, the majority of study participants
were not in treatment. Only three clinical trials were composed
exclusively of in-treatment substance abusers (38, 40, 42) (see
Table 1).
Several case management models have been identified in the
literature [see (18)]. The term “generalist case management” was
assigned to four clinical trials that did not specify a conceptual
or working name for the model of case management that was
used. The term “intensive case management” was retained for
the four trials using the term, although none specified what the
term “intensive” meant. Six trials described case management
as “strengths-based,” three as “Assertive Community Treatment”
(ACT) and four were labeled as “other”, as they referred
to case management using an unusual term: hybrid case
management (49), outreach case management (38), coordinated
care management (12, 59) or probation case management (60).
Ten of the selected trials reported using both supervision and a
manual/protocol to monitor quality control and fidelity of the
case management intervention. Three trials used a manual, but
not supervision, and conversely, three trials used supervision, but
not a manual. Five trials used neither a manual nor supervision.
Out of the 7,431 unduplicated participants randomized in
the 21 clinical trials, 6,179 were re-contacted at the first follow-
up point, which means an overall follow-up rate of 83.2%.
First follow-up moments for clinical trials ranged from 1.5 to
12 months for one of the studies. The modal first follow-up
assessment was 6 months. Among the 21 clinical trials, seven
had follow-up rates of 100% because information came from
administrative records. Five trials had follow-up rates of 90.0–
99.9%, 3 trials had rates between 80.0 and 89.9% and 5 trials
had rates between 70.0 and 79.9%. One trial had unsatisfactory
follow-up rates below 50%. Sample and follow-up rates were
not used when follow-up data consisted of participants who had
provided data at only one of multiple follow-up points. In some
instances, it was not possible to identify exact sample sizes at each
follow-up measurement due to unclear information provided in
the retrieved publications.
Synthesized Findings
All 21 clinical trials (31 studies in total) that reported a
comparison of case management (CM) and TAU on one or
more outcome indicators were included in the initial meta-
analysis. The overall effect size for case management compared to
TAU across all outcome categories and moments was small and
positive, but statistically significant (z = 3.34, p < 0.001) with a
mean effect of SMD = 0.179 (95% CI [0.07–0.28] (see Figure 2).
Observed effect sizes were positive for 16 of the 21 studies, with
five exceptions (12, 36, 49, 63, 64). Overall effect size estimates for
the clinical trials ranged from−0.202 (64) to 1.707 (38).
There was little evidence for publication bias, as a visual
examination of a funnel plot of standard errors appeared
relatively symmetric (see Figure 3). Based on the trim-and-
fill method, one effect size was added, and so the estimated
overall treatment effect changed slightly (from 0.179 to 0.170).
Egger’s intercept test confirmed that there was little evidence for
publication bias (t = 1.38, df = 19, p= 0.18).
We found some evidence for heterogeneity between studies.
The estimate of the systematic between-study variance is equal
to 0.018, I² is equal to 35.59. This means that about 36% of
the variance in observed effect sizes does not seem due to
random sampling variance, but rather to systematic variation
between studies. Despite this relatively large proportion of
variance, the Q-test showed that this variance is statistically
not significant when using a significance level of 0.05 (Q =
31.05, df = 20, p = 0.06). This does, however, not exclude
the possibility that there are moderator variables affecting
case management outcomes. Therefore, we performed several
moderator analyses.
The effect of case management was studied using 10 different
outcome types that were categorized into two broad groups:
(1) treatment tasks (linkage with substance abuse and ancillary
services, retention in substance abuse and ancillary services,
and attitudes toward treatment) and (2) personal functioning
outcomes (substance use, health status, legal involvement, risk
behavior, and social functioning) (25). Of the 21 trials, 19
contained treatment task outcomes, and 15 trials reported
personal functioning outcomes. Two separate meta-analyses
were performed for these two categories of outcomes.
Case Management and Treatment Tasks
For treatment tasks, a positive effect size was found in 17 (out of
19) trials ranging from 0.037 (39) to 1.707 (38) (see Figure 4).
Only two trials showed a (very small) negative effect size for
treatment tasks (49, 63). Seven of the trials had effect sizes above
0.5, what can be considered as a moderate effect (66). Overall, a
weak to moderate effect of CM was found regarding treatment-
related tasks, SMD = 0.33, 95% CI [0.18, 0.48]. Again, no clear
evidence for publication bias was found.
Based on separate meta-analyses, we estimated the effect
sizes for each of the five treatment tasks. The largest effect
size was found for retention in substance abuse treatment
(SMD = 0.47, 95% CI [0.13, 0.81]). Smaller effect sizes
were found for linkage with substance abuse services (SMD
= 0.23, 95% CI [0.11, 0.35]), satisfaction with treatment
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FIGURE 2 | Forest plot of Case management vs. TAU: Overall CM effect across outcome categories.
FIGURE 3 | Funnel plot of Case management vs. TAU comparison: Overall CM effect across outcome categories.
(SMD = 0.17, 95% CI [−0.04, 0.38]), retention in non-
substance abuse services (SMD=0.12, 95% CI [−0.01, 0.25])
and linkage with other types of services (SMD = 0.11, 95%
CI [−0.11, 0.34]).
Case Management and Personal Functioning
Of the 15 clinical trials with personal functioning outcomes,
all but four had positive effect sizes that ranged from 0.003
(53) to 0.608 (62) (see Figure 5). Three studies had a very
small negative effect size for functioning outcomes (12, 36,
49), but one study reported a negative effect size of −0.34
(64). Effect sizes were in general very small, including only
three trials (39, 52, 55) with an effect size >0.20 (66) and
two other studies (39, 60) with an effect size around 0.20.
The overall SMD for personal functioning outcomes (SMD =
0.06, 95% CI [−0.02, 0.15]) was very small and statistically
not significant. A funnel plot does not give evidence for
publication bias.
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FIGURE 4 | Forest plot Case management vs. TAU: Treatment related tasks.
Based on separate meta-analyses, we calculated the effect
sizes for the five personal functioning outcomes. The biggest,
although small and non-significant effects were found for social
functioning (e.g., housing, employment) (SMD = 0.14, 95% CI
[−0.01, 0.28]) and substance use outcomes (SMD = 0.10, 95%
CI [−0.02, 0.21]). Even smaller (positive) effects favoring case
management were found for risk behavior (SMD = 0.05, 95%
CI [−0.07, 0.17]) and legal involvement (SMD = 0.02, 95%
CI [−0.07, 0.10]), while a similarly small negative effect was
found regarding health outcomes (SMD=−0.16, 95%CI [−0.40,
0.08]). None of these effects, however, were statistically different
from zero.
Moderators
Six moderator variables were tested for their impact on the
efficacy of case management, i.e., model, treatment status, setting,
population, and intervention quality (manual or supervision).
Studies were characterized by the type of case management
model they used. The highest effect sizes were found for generalist
CM (k = 4): SMD=0.32, 95% CI [−0.05, 0.68], the lowest for
Assertive Community Treatment (k = 3): SMD = 0.01, 95%
CI [−0.25, 0.27] (see Figure 6). Estimated effect sizes were very
similar for strengths-based CM (k = 6): SMD = 0.22, 95% CI
[0.05, 0.38], intensive case management (k = 4): SMD = 0.22,
95%CI [0.06, 0.38], and for other types of CM (k = 4): SMD =
0.20, CI = [−0.33, 0.72]). Differences between CM models in
the size of the intervention effect were statistically not significant
(Q= 2.57, df = 4, p= 0.63).
Included studies were categorized as having participants who
could be either “in” or “out” of treatment when the intervention
started. Because the treatment status could vary within studies,
we performed two separate meta-analyses. If the treatment status
was ‘in’, the estimated mean effect was 0.18 (k = 3). If the
treatment status was “out,” the overall effect size was very similar
(SMD= 0.17, k= 19).
Studies were characterized as having participants in one
of four types of settings at the time the study started:
community/street (SMD = 0.16), criminal justice system (SMD
= 0.20), substance abuse treatment (residential, outpatient,
or mixed) (SMD = 0.23), or welfare offices (SMD = 0.19).
Differences between these four categories appeared to be very
small and statistically not significant (Q= 0.24, df = 3, p= 0.97).
Studies were characterized by the primary type of substance
use, either alcohol, poly substance use or IDU. Although the
estimated effect size for studies targeting injectable drug users
was considerably higher (SMD = 0.33 for IDUs vs. 0.18 for poly
substance users, and 0.03 for alcohol abusers), the moderating
effect of the type of population on CM outcomes was statistically
not significant (Q= 1.29, df = 2, p= 0.52).
Clinical trials were identified as having methods in place
to promote the fidelity with which the intervention was
implemented, one of these being amanual/protocol and the other
clinical supervision. No significant difference in estimated effect
size was found between studies with (SMD = 0.20) and without
supervision (SMD = 0.16) (Q = 0.10, df = 1, p = 0.75). Also,
no significant difference was found between studies with (SMD
= 0.17) and without manual (SMD = 0.19) that described the
intervention in detail. Effect sizes were very similar (Q = 0.05,
df = 1, p= 0.83).
Risk of Bias
We assessed all included studies (n = 31) for risk of bias, since
several clinical trials included ≥1 publication/study that focused
on specific outcomes or follow-up moments. We distinguished
between following types of bias: selection bias, performance bias,
attrition bias, detection bias and reporting bias [see (32)]. For
each type of bias, studies were judged to be at “low,” “high” or
“unclear” risk of bias.
Eighteen studies (11 clinical trials) reported an adequate
randomization method and were judged to be at low risk of bias
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FIGURE 5 | Forest plot of Case management vs. TAU: Personal functioning outcomes.
for “Random Sequence Generation,” 10 studies (4 clinical trials)
were at high risk of bias, while the risk was unclear in 3 studies.
Four early studies (7, 36, 37, 42) did not apply a systematic
method of sequence generation. Similarly, 18 studies (13 clinical
trials) described adequate concealment of the allocation sequence
and were at low risk of bias for “Allocation Concealment,” 8
studies (4 clinical trials) did not report an adequate procedure
for allocation concealment and in 5 studies this risk was deemed
unclear. Due to the type of intervention, participants and staff
could not be blinded for receiving/providing case management.
Still, blinding of participants and personnel (performance bias)
was assessed to be at low risk of bias in all studies (21 trials),
as it was deemed unlikely that knowledge of receiving case
management will have affected outcomes. Researchers reported
blinding of outcome assessors in 20 studies (15 clinical trials),
which were assessed to be at low risk of detection bias. The risk
of detection bias was high in 6 studies (2 clinical trials), and
in 5 studies the risk was unclear. Follow-up rates were high in
most studies, because at least part of the outcome data were
collected using administrative records. One trial had very low
follow-up rates (<50%) and 15 trials had a high follow-up rate
≥80%. Attrition bias was judged as high risk in 11 studies (6
clinical trials), primarily due to follow-up rates <70% for at least
some outcome areas. The risk of within-study selective outcome
reporting was deemed low in most studies (n = 23; 17 trials),
while high risk of reporting bias was observed in 7 studies (3
clinical trials) and “unclear” in 1 study.
DISCUSSION
Summary of Findings
The current study examined the effects of case management
regarding various indicators of recovery and service utilization,
updating results from two previous meta-analyses (2, 25)
and adding effect sizes for various types of outcomes to
available systematic reviews (14, 27–29). Outcomes were
clustered around 5 personal functioning and 5 treatment-related
outcomes as described elsewhere (25). The primary results
from the earlier studies were supported: case management
was significantly more effective than TAU conditions for
improving outcomes, although the overall effect was small
(SMD = 0.18). The effect size was significantly larger for
treatment related tasks (SMD = 0.33) than for personal
functioning outcomes (SMD = 0.06), questioning its
additional value in individuals’ recovery process. However,
substantial heterogeneity was observed between as well as
within studies.
The findings suggest a positive role for case management
over standards of care, but two factors make it difficult to
fully understand the findings. First, numerous diverse outcome
indicators (>450) are presented in clinical trials, including
reduced substance use and criminal involvement, improved
parenting skills and overall well-being, and linkage with
treatment. Such broad expectations of a single intervention
seem unwarranted, “as it is unlikely that any single psychosocial
intervention can affect so many different areas of participants’
lives” [(25), p. 614). Second, the TAU comparisons varied
widely in their intensity, providing very different comparisons
to case management. In ten of the trials, the TAU comparison
was “existing referral practices,” a broad category that was
usually ill-defined. In three trials, the comparison condition
was either residential or aftercare treatment, both of which
would quite possibly be more intensive than case management.
Finally, in four trials TAU actually consisted of probation or
parole, which is certainly an intensive comparison condition
given the possibility of individuals being incarcerated. The
finding that case management had a weak to small effect
across all outcomes, even when some of the comparison
conditions were relatively intense, suggests that the reported
effect sizes are conservative and would have been larger if
case management was compared to no treatment or waitlist
controls (25).
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FIGURE 6 | Forest plot of Case management vs. TAU according to CM model.
Differential Efficacy for Treatment Task and
Personal Functioning Outcomes
Previous meta-analyses have suggested a differential effect of case
management based on the type of outcomes being considered.
One group of outcomes—treatment tasks—focused on the
process of treatment, that is, do individuals link with and
stay involved in both substance abuse treatment and ancillary
substance abuse-related services. Attitudes toward attending
treatment are also part of treatment task outcomes. The second
group of outcomes consists of aspects of psychosocial and
behavioral functioning that are generally the primary focus of
substance abuse treatment. These areas encompass improved
functioning regarding substance use, physical and psychological
health, legal involvement, social status (housing, employment,
family relations), and risk behavior. A clinically important
and statistically significant difference was observed in case
management’s impact on treatment task outcomes compared to
personal functioning outcomes [see also (2, 25)]. Effect sizes for
the highest personal functioning areas, social functioning and
substance use, were considerably lower compared with effect
sizes for following treatment tasks: retention in substance abuse
services and linkage with substance abuse and ancillary services.
Similar results were found in meta-analyses of case
management with other mental health populations (21, 67, 68).
Given the primary goals of case management (to help individuals
identify needed services, facilitate linking with these services,
monitor treatment participation and retention, coordinate
service provision, and advocate on clients’ behalf) (31, 69), its
greater effect on treatment tasks is not surprising. The findings
support an obvious premise: if individuals with SUDs do not
link with and remain in treatment, especially in substance
abuse services, they cannot benefit from these services (25).
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Consequently, case management should be regarded as a missing
link in substance abuse treatment (24, 70).
Case Management’s Role in
Supporting Recovery
The emerging international (mental health) recovery movement
has stressed the importance of personal and subjective
experiences of recovery [e.g., (71, 72)], besides “clinical
recovery.” The latter refers to the absence of symptoms and
illness ((i.e. most personal functioning outcomes) (73, 74), while
“personal recovery” refers to a deeply personal process of change
and “living a satisfying, hopeful and contributing life, within the
limitations imposed by illness” [(75), p. 15]. Addiction recovery
has been defined in more behavioral terms and is characterized
as involving control over substance use, global health and
well-being, and active citizenship (or community participation)
(76, 77). Only a few studies selected for this review have included
measures of personal recovery like quality of life and overall
daily functioning, despite the recognition of SUD as a chronic
relapsing disorder (17). The effect of case management on
personal functioning outcomes found in this meta-analysis was
weak to small, and only for employment and housing outcomes
(social functioning, SMD = 0.14) and substance use (SMD
= 0.10) a weak effect was found. A weak, negative effect was
found for health outcomes (SMD = −0.16), a combination of
physical and mental health indicators, typically measured from
a clinical recovery perspective. Recovery should be regarded as
a long process involving several life domains and abstinence
is not a necessary, nor a sufficient marker of recovery, as it
concerns a personal and experiential journey to life satisfaction
and well-being (72). The transition from early stages of recovery
to ‘stable recovery’ averages around 5 years, with the recognition
that there are multiple pathways to recovery (78).
All models of case management have in common the goal
of linking persons with SUDs and their families with needed
resources in order to promote personal functioning and recovery
(57). Linking with and effective use of community resources and
services addresses their needs for substance abuse treatment,
safe housing, improved employment, management of health
problems, and avoiding legal problems. Resolution of these
problems should increase individuals’ opportunities to effect
recovery. Case management further promotes that persons with
SUDs keep on using these services and stay in treatment (14,
28, 41). Consequently, case management is thought to directly
affect treatment-related outcomes (e.g., linkage, retention) and,
by doing so, to indirectly impact on personal functioning
outcomes (e.g., alcohol and drug use, employment, health status,
family relations) and thus recovery.
Although case management was not found to be directly
associated with improved personal functioning, two other
mechanisms may be in operation (14, 25, 56). First, case
management may have an indirect effect on separate personal
functioning outcomes and overall recovery through its impact
on treatment tasks such as linking and retention. Treatment
participation and retention are widely documented predictors of
remission and recovery (73, 79). For example, recently released
parolees with SUDs who were receiving case management, were
retained in treatment significantly longer than persons not
receiving this intervention (60). Longer retention was associated
with reduced substance use, less criminal justice involvement and
risk behavior, and improved housing and employment situations
at follow-up. Consequently, improved functioning should be
viewed as a result of case management’s ability to improve linkage
and retention rather than as a direct effect.
Second, personal functioning outcomes—and eventually
recovery—may be enhanced by combining case management
with specialized skills and activities (e.g., a strengths approach)
(25). Case management may include a variety of direct
interventions, ranging from providing information and advice
and substance abuse counseling to being clients’ primary
therapist in clinical models of case management (18). For
example, clinical case managers receive specialized training
to combine therapeutic support and case management (80).
In this instance, it may be warranted to expect that case
management contributes to improved personal functioning
outcomes such as reductions in psychiatric symptoms and
improved well-being (25, 81). Case management can also be
combined with other interventions such as risk reduction
activities, motivational interviewing, and recovery management
[see (51, 62)]. Expanded case management services have been
frequently applied among substance users with additional mental
health (82, 83) and HIV/AIDS problems (49, 84). It is a standard
part of comprehensive case management models like intensive
case management (53, 55) and Assertive Community Treatment
(ACT) (54, 64). Importantly, various studies were excluded
from this review, as they offered comprehensive interventions
combining case management with other viable approaches
(e.g., cognitive behavioral therapy, Housing First programs), in
which case management effects could not be disentangled from
these additional interventions. Such promising combinations
are worthwhile reviewing, although separating specific case
management effects will be challenging. These observations
illustrate that the variety between case management conditions
(from brief models to comprehensive, long-term approaches)
may at least be as diverse as the variety observed in TAU
conditions, which is likely to affect case management’s efficacy.
Toward a Recovery-Oriented
Research Agenda
The increased interest in case management resulted in the
addition of several new trials (especially from outside the US)
in this updated meta-analysis and over 130 recent studies (non-
randomized, quasi-experimental, and observational studies) were
excluded, primarily because they didn’t apply a randomized study
design or did not focus exclusively on substance users. Case
management is often used to address severely disadvantaged
populations with multiple and complex needs. This does not
only challenge the randomization process in real-life settings
and leads to the adoption of less rigid study methodologies
(85), but also reduces the likelihood of finding large effect
sizes (14). Also, the finding that case management is effective
for improving linkage has contributed to its incorporation in
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comprehensive treatment programs (86–88) and to its acceptance
as a mainstream intervention. In some clinical trials (89–91),
case management was even applied as a standard of care control
condition, assuming that this intervention would be inferior to
the experimental intervention. These studies were not included
in this systematic review, but should be reviewed in a separate
meta-analysis that compares case management to other active
interventions. Given the comparison with other viable (or even
evidence-based) interventions, it is likely that case management’s
efficacy will be lower than compared with TAU.
Despite the increasing popularity of quality of life and other
indicators of subjective well-being for evaluating interventions
among persons with chronic disorders (92), such outcomes
have hardly been studied in clinical trials of case management.
Although these studies have often included self-report measures
of health and substance use outcomes, they mostly refer to
high expectations and socially desirable changes (e.g., abstinence
from alcohol and drugs, no arrests, employment) rather than
to individuals’ perceived well-being and quality of life. Yet,
such measures might shed an alternative light on individuals’
situations and personal functioning outcomes (93). As case
management is primarily applied among severely affected
substance using populations, a focus on subjective and person-
centered outcomes is more likely to demonstrate the benefits
of case management in individuals’ daily lives. Introducing a
recovery perspective in controlled studies of case management
will also allow to measure its impact on individuals’ satisfaction
with life and participation in society, as well as factors directly
or indirectly affecting it. A number of trials were recently set
up or are still ongoing that could potentially fill some of these
gaps (94, 95).
Quality of the Evidence and Limitations of
This Review
According to the GRADE criteria (96), the quality of the
evidence regarding the reported outcome categories would be
rated moderate to low, primarily due to multiple risks of bias and
substantial heterogeneity, or a combination of both. About 1 in
4 studies did not describe the randomization and concealment
method adequately. Outcomes assessors were only blinded for
group allocation in 2 out of 3 studies and most studies did not
use blinding of study participants and case managers. When
outcomes are self-reported behaviors and when participants are
not blinded to study conditions, overestimation of intervention
effects is a potential risk (97). However, since administrative
data or objective outcome indicators (e.g., biological markers)
were used in at least half of the trials, this risk was minimized.
Attrition rates were not acceptable in one trial (42). Follow-
up rates sometimes differed within one trial, as several studies
used administrative records and assessments to evaluate study
outcomes. Attrition bias may limit the applicability of study
results or the power to detect between-group differences (97).
Despite low attrition in some studies, this may not be problematic
if attrition rates are similar in the experimental and control
condition (97). We observed few indications for differential
attrition rates in the included studies. Finally, publication bias
may hamper the conclusions from any systematic review. Visual
inspection of funnel plots suggested no evidence for publication
bias, and the use of the trim-and-fill method only changed effect
sizes slightly. Still, 1 in 5 studies were at high risk of reporting
bias, as only some outcome indicators were reported in retrieved
publications. Since this meta-analysis is based on published
study outcomes, we may not underestimate the likelihood of
publication bias as journals tend to publish studies including
significant findings. Yet, the fact that several of the included
RCTs generated no (or even inverse) effects favoring the case
management condition illustrates that reported outcomes are not
limited to significant positive outcomes.
This meta-analytic review has some limitations, most of which
are typical for meta-analyses (98). First, all included studies
were randomized clinical trials (25). Quasi-experimental trials
are another source of evidence for case management studies,
but these were excluded as we focused on studies in which all
subjects were randomly assigned to either case management or
a comparison condition. Second, even though all studies in this
review were randomized, substantial methodological differences
were observed (25). For example, studies used a variety of
instruments to measure personal functioning outcomes, and
at least 15 different substance use measures were used. This
resulted in numerous different outcomes per outcome category.
Third, fairly distinct populations were included in the clinical
trials, e.g., persons with dual diagnosis, female welfare recipients,
homeless alcohol dependent men, HIV infected intravenous
drug users and incarcerated drug offenders. Even within these
groups, study participants had diverse treatment needs, which
may affect case managers’ activities (14) Moreover, individual-
level characteristics determine the effects of an intervention.
For instance, there is evidence that SUDs are associated with
various individual characteristics such as gender, comorbid
disorders and psychosocial functioning [e.g., (99)], and it is
possible that the likelihood of success of case management is
associated with such factors. Ideally, this meta-analysis should
have been based on the raw data of all individuals included in
the selected clinical trials, so that we could perform a multilevel
analysis accounting for covariates at the within-study level, in
addition to covariates at the between-study level. By modeling
the interaction effect of these individual characteristics and the
intervention, we could have evaluated the moderating effects
of these characteristics. In this meta-analysis, however, we had
to rely on effect sizes summarizing effects for whole samples
of participants, since the raw data were not available. It would
still be interesting to study moderating effects of individual
characteristics aggregated at sample level, but unfortunately,
individual participant characteristics were not systematically
measured and reported in the selected studies, so that we
were not able to perform such moderator analyses (with the
exception of the type of population studied). Therefore, part
of the between-study variance in treatment effects may be due
to differences in the composition of the samples in terms of
participant characteristics. Fourth, in the absence of fidelity
measures, we could not determine case management dosage or
quality, nor could we control for eventual differences through
moderator analyses (25). Fifth, we could not quantify all of the
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intervention features that might affect outcomes, although we
used several characteristics of case management as moderators to
help explain its efficacy. Case management is often characterized
as being contextual and reflective of the network of services in
which it is implemented (23), suggesting that the availability of
services influences its overall efficacy (25). Consequently, the
quality of service provision is likely to be beyond the control
of case managers, even when resources are available. Finally, all
study outcomes are characterized by substantial heterogeneity
between and within study outcomes, which can be explained by
the large variation in study populations, settings and treatment
status, but also by within study variation regarding population,
case management dosage and multiple follow-up measurements.
We tried to control for some of these influences through
moderator analyses.
CONCLUSION
Three extensive meta-analyses, including this one, have now
confirmed that substance abuse case management is efficacious
in improving important treatment-related outcomes such as
linking with and staying engaged (retention) in substance
abuse and ancillary services compared with standards of
care. Substance abuse programs often experience challenges
in delivering and coordinating ongoing support and in
providing access to additional services for persons with SUDs
and multiple and complex problems. Enhanced linking and
retention in substance abuse and ancillary services have been
associated with improved abstinence rates (100), less frequent
hospital readmissions (101), and adequate functioning in the
community (102). Linking with and engaging in treatment are
therefore necessary prerequisites to persons with SUD having
an opportunity to benefit from these services. Although most
models of case management seem to be equally effective in
promoting these outcomes, this point is still not clear given the
shortage of (comparative) trials of models of case management.
Substance abuse case management did not have a significant
direct effect on personal functioning outcomes compared with
standards of care. The positive, but limited impact of this
intervention on substance use and other clinical recovery-
related outcomes is supposed to be mediated by case managed
individuals’ use of substance abuse and ancillary services and
participation in treatment. Consequently, case management
should be an integral part of comprehensive, wrap-around
interventions to promote linkage and treatment participation
and retention, and indirectly, personal functioning outcomes
and recovery.
Further areas of research are at least 3-fold. First, studies that
continue to include personal functioning outcomes should use
methodological strategies that allow to assess the relationship
between treatment linkage and retention on the one hand,
and improved functioning outcomes on the other hand.
Second, additional research is needed regarding some outcome
categories (e.g., retention in and satisfaction with treatment),
as case management is most likely to favor this type of
understudied outcomes. Some type of outcomes have hardly
been assessed in case management studies (e.g., quality of life,
subjective well-being), although such indicators of personal
recovery may enhance our knowledge substantially. Also,
intensity and dosage of case management have been poorly
studied. Third, despite the evidence that case management
works for some specific purposes and populations, it remains
largely unknown how it works and for whom at various
stages of the treatment continuum. Future reviews should
consider including quasi-experimental studies, since such
designs usually resemble real-life settings more closely and
the eventual question whether something works is whether
it works in practice rather than under strictly controlled
study conditions.
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